Abstract:Raloxifene, a selective estrogen receptor modulator, displays benefits for Alzheimer's disease (AD) prevention in postmenopausal women as hormonal changes during menopause have the potential to influence AD pathogenesis, but the underlying mechanism of its neuroprotection is not entirely clear. In this study, the effects of raloxifene on amyloid-beta (A beta) amyloidogenesis were evaluated. The results demonstrated that raloxifene inhibits A beta(42) aggregation and destabilizes preformed A beta(42) fibrils through directly interacting with the N-terminus and middle domains of A beta(42) peptides. Consequently, raloxifene not only reduces direct toxicity of A beta(42) in HT22 neuronal cells, but also suppresses expressions of tumor necrosis factor-alpha and transforming growth factor-beta induced by A beta(42) peptides, and then alleviates microglia-mediated indirect toxicity of A beta(42) to HT22 neuronal cells. Our results suggested an alternative possible explanation for the neuroprotective activity of raloxifene in AD prevention.

Raloxifene alleviates amyloid-β-induced cytotoxicity in HT22 neuronal cells via inhibiting oligomeric and fibrillar species formation.